Caprihans India Limited
601, ICC Trade Towers,
Pune 411016 India

Tel +91 20 6749 0100
direct@bilcare.com
www.bilcare.com

Bilcare Research

10 August 2026

To,
BSE Ltd
Dept. of Corporate Services,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001
Scrip Code No – 509486

Sub: Outcome of Board Meeting

Dear Sir/Madam,

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we are pleased to inform you that the Board of Directors of the Company at its meeting held on Monday, 10 August 2026 have approved and taken on record the following:

A. Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended on 30 June 2026 (enclosed);

B. Limited Review Report issued by the Statutory Auditors of the Company for the quarter ended on 30 June 2026 (enclosed);

C. Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, this is to inform you that Mr. Avinash S. Joshi (DIN: 05320116) vide communication dated 10 August 2026, has tendered resignation as an Independent Director of the Company, with effect from close of business hours on 10 August 2026. Consequently, he shall also cease to be a Member of the Audit Committee, Nomination and Remuneration Committee and from the Chairmanship of Audit Committee of the Company.

   The Board place on record its sincere appreciation for the valuable contribution and guidance provided by Mr. Mr. Avinash S. Joshi during his association with the Company as Independent Director of the Company. The details as required under SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 along with copy of resignation letter are enclosed herewith as Annexure - I.

D. In view of the changes in the Board of Directors, the Board has approved the changes in the composition of Audit Committee and Nomination and Remuneration Committee with effect from 11 August 2026. The details are enclosed herewith as Annexure - II.

The Board meeting commenced at 06:00 P.M. and concluded at 08:30 P.M. (IST).

You are requested to take the same on record and confirm receipt of the same.

Thanking you,

Yours faithfully,

For Caprihans India Limited

Rajesh P. Likhite
Company Secretary & Compliance Officer
Caprihans India Limited
Adobe Acrobat version:
2025.001.20997

Rajesh P. Likhite
Company Secretary & Compliance Officer

Encl: as above

Caprihans India Limited
Registered Office: 1028 Shiroli, Rajgurunagar, Pune 410505 Tel : +91 21 35647300
Email : direct@bilcare.com Website : www.bilcare.com
CIN : L29150PN1946PLC232362
Unaudited Standalone Statement of Financial Results for the Quarter ended June 30, 2026

(Rs. In Crores)

Sr No	Particulars	Quarter ended			Year Ended
		June 30, 2026	March 31, 2026	June 30, 2025	March 31, 2026
		(unaudited)	(audited)	(unaudited)	(audited)
1	**Income**				
	(a) Revenue From Operations	216.96	178.85	177.85	697.07
	(b) Other Operating Income	3.20	2.96	4.04	13.18
	Total Revenue from Operations	**220.16**	**181.81**	**181.89**	**710.25**
	(c) Other Income	1.82	18.41	3.02	27.83
	Total Income (1)	**221.98**	**200.22**	**184.91**	**738.08**
2	**Expenses**				
	(a) Cost of Materials Consumed	138.53	120.86	126.75	481.37
	(b) Purchase of Traded Goods	-	0.01	-	0.02
	(c) Changes in Inventories of Finished Goods, Work-in-Progress	(3.48)	(7.58)	(2.62)	(4.29)
	(d) Employee Benefits Expense	17.80	17.48	17.94	70.88
	(e) Finance Costs	18.67	18.24	19.05	74.40
	(f) Depreciation and Amortisation Expense	10.76	11.14	10.93	44.90
	(g) Other Expenses	32.69	33.84	30.51	121.78
	Total Expenses (2)	**214.97**	**193.99**	**202.56**	**789.06**
3	**Profit/(Loss) Before Exceptional Items and Tax (1-2)**	**7.01**	**6.23**	**(17.65)**	**(50.98)**
4	**Exceptional Item Net (Expense)/Income**	-	0.08	-	(1.64)
5	**Profit/(Loss) Before Tax after Exceptional Item (3+4)**	**7.01**	**6.31**	**(17.65)**	**(52.62)**
6	**Tax Expense**				
	(a) Current Tax	-	-	-	-
	(b) Adjustment of Tax Relating to Earlier Years	-	-	-	-
	(c) Deferred Tax	-	-	(4.10)	(4.45)
	Total Tax Expense (6)	**-**	**-**	**(4.10)**	**(4.45)**
7	**Profit/(Loss) for the Period (5-6)**	**7.01**	**6.31**	**(13.55)**	**(48.17)**
8	**Other Comprehensive Income**				
	a. Items that will not be reclassified to Profit or Loss				
	(i) Remeasurement Gain/(Losses) on Defined Benefit Plans	(1.07)	(0.84)	(0.17)	2.27
	(ii)Tax Impact	-	-	0.04	0.12
	Total Other Comprehensive Income (8)	**(1.07)**	**(0.84)**	**(0.13)**	**2.39**
9	**Total Comprehensive Income for the Period (7+8)**	**5.94**	**5.47**	**(13.68)**	**(45.78)**
10	Paid-up Equity Share Capital (Face Value of Rs 10 Per Share)	17.62	15.91	14.62	15.91
11	Reserves Excluding Revaluation Reserves as Per The Balance Sheet of The Respective Accounting Year	-	-	-	(169.93)
12	**Earnings per Share (Not Annualised)**				
	Basic EPS (Amount in Rs.)	4.25	4.31	(9.27)	(32.88)
	Diluted EPS (Amount in Rs.)	3.98	3.52	(9.27)	(32.88)

PATKI & SOMAN
F. R. No. 107830W
PUNE
Chartered Accountants

Ankita K

Caprihans India Limited
Registered Office: 1028 Shiroli, Rajgurunagar, Pune 410505 Tel : +91 21 35647300
Email : direct@bilcare.com Website : www.bilcare.com
CIN : L29150PN1946PLC232362

Notes to Standalone Financial Results:

1 The Company is primarily engaged in Pharma Packaging Solutions, and its products are covered under a single reportable segment.

2 The above results have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

3 Bilcare Research GmbH a wholly owned subsidiary of the Company has been consolidated in the Consolidated financial results of the Group for the period ended June 30, 2026.

4 During the financial year ending March 31, 2025, the Company on 3rd and 5th December 2024 had approved for issue and allotment of 48,00,000 Convertible Warrants (hereinafter referred to as "Warrants") at an issue price of Rs. 200/- each on a preferential basis for an aggregate amount of Rs. 96.00 Crores, against receipt of Rs.24.00 crores as Warrant Subscription; amount being equivalent to 25% of the total consideration, with each Warrant convertible into one equity share of the Company within a period of 18 months from the date of allotment of Warrants at a conversion price of Rs.200/ per Warrant (including Rs. 190 per share towards share premium), to the Allottees ("Allottees") of share warrant. As on 31st March 2026, the company had 20,20,000 warrants outstanding, for which Rs.10.10 Crores had been received as warrant subscription amount. During the quarter ended, June 2026 the company received INR 25.58 Crores being 75% of the 17,05,000 outstanding warrants.
Conversion option attached to 3,15,000 share warrants were not exercised within 18 months from the date of allotment i.e. 05th December 2024; hence, the Board of Directors of the Company in the meeting dated 05th June 2026 has approved the forfeiture of the money received of Rs.1.58 Crores from the share warrant holders which has been transferred to capital reserve.

5 During the year, the Company has redeemed 2,55,75,500 0.1% Redeemable Preference Shares (RPS) of Rs. 10/- each issued to Bilcare Limited and the same stands reduced to the equivalent amount

6 In respect of the arrangement with Bilcare Limited (Bilcare) for the repayment of principal and interest on the public fixed deposit liability taken over by the Company as per the Business Transfer Agreement, the outstanding as at June 30, 2026 is Rs. 2.34 crores (including interest) which was fully earmarked and maintained with PFD Escrow account. In respect of these PFDs, Bilcare had received an order from the National Company Law Tribunal, Mumbai, dated 05th June 2026, directing Bilcare to transfer the outstanding amount to the Investor Education and Protection Fund on or before 15th July 2026 and to publish an advertisement/ notice of the same in vernacular and English newspapers. Accordingly, the outstanding amount has been transferred to the Investor Education and Protection Fund and the statutory compliances related to Public fixed deposit is the responsibility of Bilcare Limited.

7 The Company follows a revaluation model for the purpose of subsequent measurement of its Property, Plany & Equipement (PPE). The company has revalued all classes of PPE as on 01st April, 2026 based on independent valuer's revaluation report. Accordingly, the company has recognized an amount of Rs. 21.03 Crores in its revaluation reserve.

8 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 10, 2026. The results have been reviewed by the Statutory Auditors of the Company.

9 The Company has carried forward business losses / unabsorbed business depreciation under the Income Tax Act, 1961 which can be set off against the Profits of the Company. Accordingly, no provision for current tax has been considered necessary.

10 In consideration of the unabsorbed carry forward losses, the Company has decided not to recognize Deferred Tax Assets.

11 Previous periods' figures have been re-grouped / re-classified / re-arranged wherever necessary.

12 The figures for the quarter ended March 31, 2026 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the financial year.

For Caprihans India Limited

Ankita K

Ankita J. Kariya
Managing Director

PATKI & SOMAN
F. R. No. 107[illegible]30W
PUNE
Chartered Accountants

Pune
August 10, 2026

PATKI & SOMAN
Chartered Accountants

HEAD OFFICE : 101/102, Parmesh Plaza, 1213, Sadashiv Peth, Near Hatti Ganpati, Pune - 411 030.
Telephone : 24456748, 24446748 Web : www.patkiandsoman.com E-mail : patkiandsoman@gmail.com

Ref. :

Date :

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors
Caprihans India Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Caprihans India Limited ("the Company") for the quarter ended June 30, 2026 ("the Statement"), being submitted by the company pursuant to the requirement of Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. The Company's Board of Directors is responsible for the preparation and fair presentation of the Statement in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013("the Act") as amended, read with relevant rules thereunder and other accounting principles generally accepted in India and is in compliance with Regulation 33 and 52 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard ("Ind AS") specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the

F. R. No. 10[illegible]30W
PUNE

information required to be disclosed in terms of Regulation 33 and 52 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. We draw attention to Note 6 pertaining to the arrangement and agreement with Bilcare Limited ("the Bilcare") in respect of repayment of principal and interest on the Public Fixed Deposit liability taken over by the Company, having carrying amount of Rs. 109.60 Crores as at March 27,2023 as per the Slump Sale Agreement, which had matured but remained unpaid by the Pharma Packaging Innovation (PPI) division of Bilcare. As per the agreement the statutory compliances related to Public Fixed Deposit under Companies Act, 2013 is responsibility of Bilcare. As on June 30, 2026 the total outstanding amount of the aforesaid Public Fixed Deposit liability including interest is Rs.2.34 Crores. In respect of these PFDs, Bilcare had received an order from the National Company Law Tribunal, Mumbai, dated 05th June 2026, directing Bilcare to transfer the outstanding amount to the Investor Education and Protection Fund (IEPF) on or before 15th July 2026. As per information and details provided to us, the said amount has been transferred to the IEPF.
Our conclusion is not modified in respect of this matter.

For PATKI AND SOMAN
CHARTERED ACCOUNTANTSs
Firm Registration No. 107830W

J S Kulkarni

F. R. No.
107830W
PUNE

SHRIPAD S. KULKARNI
(Partner)
Membership No. 121287
Place: Pune
Date: 10th August 2026
UDIN: 26121287BVSGEH3908

Caprihans India Limited
Registered Office: 1028 Shiroli, Rajgurunagar, Pune 410505 Tel : +91 21 35647300
Email : direct@bilcare.com Website : www.bilcare.com
CIN : L29150PN1946PLC232362

Unaudited Consolidated Statement of Financial Results for the Quarter Ended June 30, 2026

(Rs. In Crores)

Sr No	Particulars	Quarter ended			Year Ended
		June 30, 2026	March 31, 2026	June 30, 2025	March 31, 2026
		(unaudited)	(audited)	(unaudited)	(audited)
1	**Income**				
	(a) Revenue From Operations	218.19	180.11	177.85	701.91
	(b) Other Operating Income	3.20	2.96	4.04	13.18
	Total Revenue from Operations	**221.39**	**183.07**	**181.89**	**715.09**
	(c) Other Income	1.82	18.41	3.02	27.83
	Total Income (1)	**223.21**	**201.48**	**184.91**	**742.92**
2	**Expenses**				
	(a) Cost of Materials Consumed	138.53	120.86	126.75	481.37
	(b) Purchase of Traded Goods	1.26	0.90	-	4.06
	(c) Changes in Inventories of Finished Goods, Work-in-Progress	(3.48)	(7.58)	(2.62)	(4.29)
	(d) Employee Benefits Expense	18.40	17.90	17.94	72.83
	(e) Finance Costs	18.67	18.25	19.05	74.43
	(f) Depreciation and Amortisation Expense	10.76	11.14	10.93	44.90
	(g) Other Expenses	32.86	33.05	30.52	119.43
	Total Expenses (2)	**216.99**	**194.52**	**202.57**	**792.73**
3	**Profit/(Loss) Before Exceptional Items and Tax (1-2)**	**6.22**	**6.96**	**(17.66)**	**(49.81)**
4	**Exceptional Item Net (Expense)/Income**	-	0.08	-	(1.64)
5	**Profit/(Loss) Before Tax after Exceptional Item (3+4)**	**6.22**	**7.04**	**(17.66)**	**(51.45)**
6	**Tax Expense**				
	(a) Current Tax	-	-	-	-
	(b) Adjustment of Tax Relating to Earlier Years	-	-	-	-
	(c) Deferred Tax	-	-	(4.10)	(4.45)
	Total Tax Expense (6)	**-**	**-**	**(4.10)**	**(4.45)**
7	**Profit/(Loss) for the Period (5-6)**	**6.22**	**7.04**	**(13.56)**	**(47.00)**
8	**Other Comprehensive Income**				
	a. Items that will not be reclassified to Profit or Loss				
	(i) Remeasurement Gain/(Losses) on Defined Benefit Plans	(1.07)	(0.84)	(0.17)	2.27
	(ii)Tax Impact	-	-	0.04	0.12
	b. Items that will be reclassified to Profit or Loss				
	(i)Exchange difference on Translation of Foreign Operation	(0.01)	(0.10)	-	0.01
	Total Other Comprehensive Income (8)	**(1.08)**	**(0.94)**	**(0.13)**	**2.40**
9	**Total Comprehensive Income for the Period (7+8)**	**5.14**	**6.10**	**(13.69)**	**(44.60)**
10	Paid-up Equity Share Capital (Face Value of Rs 10 Per Share)	17.62	15.91	14.62	**15.91**
11	Reserves Excluding Revaluation Reserves as Per The Balance Sheet of The Respective Accounting Year	-	-	-	(170.77)
12	**Earnings per Share (Not Annualised)**				
	Basic EPS (Amount in Rs.)	3.77	4.80	(9.27)	(32.08)
	Diluted EPS (Amount in Rs.)	3.53	3.93	(7.56)	(32.08)

Notes to Consolidated Financial Results:

1 All Standalone notes also pertain for the Consolidated financial results.

2 Bilcare Research Gmbh a wholly owned subsidiary of the Company has been consolidated in the Consolidated financial results of the Group for the quarter ended June 30, 2026.

3 The above consolidated results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 10, 2026. The results have been reviewed by the Statutory Auditors of the Company.

4 Previous periods' figures have been re-grouped / re-classified / re-arranged wherever necessary.

5 The figures for the quarter ended March 31, 2026 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the financial year.

PATKI & SOMAN
F. R. No. 107830W
PUNE
Chartered Accountants

For Caprihans India Limited

Ankitak

Pune
August 10, 2026

Ankita J. Kariya
Managing Director

INDIA

PATKI & SOMAN
Chartered Accountants

HEAD OFFICE : 101/102, Parmesh Plaza, 1213, Sadashiv Peth, Near Hatti Ganpati, Pune - 411 030.
Telephone : 24456748, 24446748 Web : www.patkiandsoman.com E-mail : patkiandsoman@gmail.com

Ref. : Date :

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of Caprihans India Limited pursuant to the Regulations 33 and 52 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015, as amended

To,
The Board of Directors
Caprihans India Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Caprihans India Limited ("the Holding Company") and its Subsidiary ('the Holding Company and it's Subsidiary together referred to as 'the Group') for the quarter ended June 30, 2026 ("the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. The Holding Company's Management is responsible for the preparation and fair presentation of the Statement in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013("the Act") as amended, read with relevant rules thereunder and other accounting principles generally accepted in India and is in compliance with Regulation 33 and 52 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The statement includes the interim financial information of one (1) foreign subsidiary i.e. Bilcare Research GmbH.

F. R. No. 107830W
PUNE

5. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard ("Ind AS") specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and 52 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We draw attention to Note 6 to the Standalone Financial Results pertaining to the arrangement and agreement with Bilcare Limited ("the Bilcare") in respect of repayment of principal and interest on the Public Fixed Deposit liability taken over by the Holding Company, having carrying amount of Rs. 109.60 Crores as at March 27,2023 as per the Slump Sale Agreement, which had matured but remained unpaid by the Pharma Packaging Innovation (PPI) division of Bilcare. As per the agreement, the statutory compliances related to Public Fixed Deposit under Companies Act, 2013 is responsibility of Bilcare. As on June 30, 2026 the total outstanding amount of the aforesaid Public Fixed Deposit liability including interest is Rs.2.34 Crores.
In respect of these PFDs, Bilcare had received an order from the National Company Law Tribunal, Mumbai, dated 05th June 2026, directing Bilcare to transfer the outstanding amount to the Investor Education and Protection Fund (IEPF) on or before 15th July 2026. As per information and details provided to us, the said amount has been transferred to the IEPF.

7. We did not review the interim financial information of one (1) foreign subsidiary, Bilcare Research GmbH, included in the Consolidated Financial Statements, whose interim financial information reflects total revenue of Rs.1.93 Crores and total Comprehensive Loss of Rs.0.80 Crores for the quarter ended on 30th June 2026, as considered in the Consolidated Financial Statements. This unaudited financial information has been furnished to us by the Holding company's management. Our conclusion on the statement, in so far as it is related to amounts and disclosures in respect of this subsidiary, is based solely on such unaudited interim financial information.
Our conclusion is not modified in respect of this matter.

For PATKI AND SOMAN
CHARTERED ACCOUNTANTS
Firm Registration No. 107830W

S S Kulkarni

F. R. No. 107830W PUNE

SHRIPAD S. KULKARNI
(Partner)
Membership No. 121287
Place: Pune
Date: 10th August 2026
UDIN: 26121287ORWFQJ4425

Annexure - I

Disclosure as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024:

Sr. No.	**Particulars**	**Details**
1	Reason for change v~~iz. appointment,~~ resignation, ~~removal, death or otherwise;~~	Resignation: Mr. Avinash S. Joshi has tendered resignation from the post of Independent Director of the Company w.e.f. closure of business hours of 10 August 2026, due to personal reasons.
2	Date of~~ appointment ~~/cessation ~~(as applicable) & term of appointment~~	Date of cessation of Mr. Avinash Joshi: w.e.f. closure of business hours of 10 August 2026.
3	Brief profile (in case of appointment)	Not Applicable
4	Disclosure of Relationships between Directors (in case of Appointment of a Director)	Not Applicable
5	Names of listed entities in which the resigning director holds directorships, indicating the category of directorship and membership of board committees, if any	Nil
6	Letter of Resignation along with detailed reason for resignation	Enclosed herewith
7	Confirmation of no other material reasons	Mr. Avinash S. Joshi has confirmed that there are no other material reasons for his resignation other than those stated in his resignation letter.

For Caprihans India Limited

Rajesh P. Likhite
Company Secretary & Compliance Officer
Caprihans India Limited
Adobe Acrobat version:
2025.001.20997

Rajesh P. Likhite
Company Secretary & Compliance Officer

Encl: as above

Avinash S. Joshi
S 3, Mayureshwar Apartment,
Opp. Z.P Satara,
Satara – 415001

---

10 August 2026

To,
Board of Directors,
Caprihans India Limited,
1028 Shiroli, Rajgurunagar,
Pune, Maharashtra, India 410505

Dear Sir/Madam,

Subject: Resignation as an Independent Director of the Company

This is to inform you that I hereby tender my resignation as an Independent Director of the Company, with immediate effect from close of business hours on 10 August 2026. Consequently, I will also be stepping down as the Member of Audit Committee and Nomination & Remuneration Committee and from the Chairmanship of Audit Committee of the Board of the Company. I hereby confirm that my decision is entirely personal and there are no other material reasons for my resignation.

Kindly acknowledge the receipt of this resignation letter and arrange to submit the necessary Forms and Intimation to Ministry of Corporate Affairs, Stock Exchange and other Statutory /Regulatory Authorities.

I take this opportunity to thank the Board members for the support extended to me during my tenure as an Independent Director of the Company.

Thanking you,

Regards,

Avinash S. Joshi
DIN: 05320116

Ankitak

Caprihans India Limited
601, ICC Trade Towers,
Pune 411016 India

Tel +91 20 6749 0100
direct@bilcare.com
www.bilcare.com

Bilcare Research

Annexure – II

Composition of Committees of the Board of Directors of Caprihans India Limited with effect from 11 August 2026

A) Audit Committee

Name of the Committee Member	Designation	Category
Mr. Kavaseri Ramaswamy Viswanathan	Chairperson	Independent Director
Mr. Sudhir Pendse	Member	Independent Director
Mrs. Ankita Kariya	Member	Managing Director

A) Nomination & Remuneration Committee

Name of the Committee Member	Designation	Category
Mr. Sudhir Pendse	Chairperson	Independent Director
Mr. Sanjeev Tole	Member	Independent Director
Mr. Pramod Toshniwal	Member	Non Executive Non Independent Director